- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03296540
CRUSHed vs. Uncrushed Prasugrel in STEMI Patients Undergoing PCI (CompareCrush)
COMPARison of Pre-hospital CRUSHed vs. Uncrushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Interventions
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The study is a two-centre, randomized, 1:1 trial comparing prehospital prasugrel initiation therapy between crushed vs. uncrushed prasugrel tablets on efficacy and safety as well as pharmacodynamics in STEMI patients.
Patients with STEMI planned for primary PCI will be screened and, if inclusion criteria are met, included at first medical contact (paramedics). After enrolment, patients will be randomly assigned (1:1) to receive 60mg prasugrel loading dose by ingesting integral or crushed tablets.
The follow-up duration is 12 months, i.e. clinical outcomes will be analysed in-hospital, at 30 days, and 12 months
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 4
Contatti e Sedi
Luoghi di studio
-
-
-
Rotterdam, Olanda, 3015 CE
- Erasmus Medical Center
-
Rotterdam, Olanda, 3079 DZ
- Maasstadziekenhuis
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Consecutive patients with STEMI planned for primary PCI:
- Deferred written informed consent within 4 hours after prasugrel loading dose
- Adult men and women aged at least 18 years
- Symptoms of acute MI of more than 30 min but less than 6 hours
- New persistent ST-segment elevation ≥ 1 mm in two or more contiguous ECG leads
Exclusion Criteria:
- Contraindication to prasugrel (e.g., hypersensitivity, active bleeding, history of previous intracranial bleed, history of any CVA including TIA, moderate to severe hepatic impairment, GI bleed within the past 6 months, major surgery within past 4 weeks)
- Patient who has received loading dose of clopidogrel or ticagrelor for the index event or are on chronic treatment of ticagrelor, or prasugrel. However, patients on maintenance dose clopidogrel for at least 7 days are included in the study (see appendix A).
- Oral anticoagulation therapy that cannot be stopped (i.e. patients requiring chronic therapy)
- Planned fibrinolytic treatment
- Patient requiring dialysis
- Known, clinically important thrombocytopenia
- Known clinically important anaemia
- Known pregnancy or lactation
- Need for a concomitant systemic therapy with strong inhibitors or strong inducers of CYP3A
- Condition which may either put the patient at risk or influence the result of the study (e.g., cardiogenic shock with severe hemodynamic instability, active cancer, risk for non-compliance, risk for being lost to follow up)
- Patient unable to swallow oral medication (i.e. intubated patients)
- Patient who have not received prasugrel loading dose in the ambulance
- Patient who vomited after randomization / receiving the loading dose prasugrel
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore attivo: Uncrushed
6 Integral tablets Prasugrel as loading dose
|
loading dose of 6 integral tablets of 10mg Prasugrel
Altri nomi:
|
Sperimentale: Crushed
6 Crushed tablets Prasugrel as loading dose
|
loading dose of 6 crushed tablets 10mg Prasugrel
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Co-primary endpoint is the percentage of patients reaching TIMI flow grade 3 of MI culprit vessel at initial angiography or a ≥70% ST-segment resolution directly post-PCI
Lasso di tempo: directly post PCI
|
To assess the efficacy of crushed vs. integral tablets of prasugrel loading dose treatment by comparing the percentage of patients reaching the co-primary endpoint of TIMI flow grade 3 of MI culprit vessel at initial angiography or a ≥70% ST-segment elevation resolution directly post-PCI.
|
directly post PCI
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Composite of death, MI, stroke, urgent revascularization and acute stent thrombosis in hospital, at 30 days and 12 months
Lasso di tempo: upto 72 hours after randomisation, at 30 days and 12 months.
|
Percentage of patients in the following: composite of death, MI, stroke, urgent revascularization and acute stent thrombosis during inhospital stay, 30 days and 12 months of study
|
upto 72 hours after randomisation, at 30 days and 12 months.
|
Composite of death, MI, urgent revascularization during inhospital, at 30 days and 12 months of study
Lasso di tempo: 30 days and 12 months
|
Percentage of patients in the following: composite of death, MI, or urgent revascularization during inhospital, 30 days and 12 months of study
|
30 days and 12 months
|
Individual endpoints during inhospital, at 30 days and 12 months of study
Lasso di tempo: upto 72 hours after randomisation, at 30 days and 12 months.
|
Percentage of patients presenting with any of the individual endpoints during inhospital, 30 days and 12 months of study
|
upto 72 hours after randomisation, at 30 days and 12 months.
|
Thrombotic bail-out with GPIIb/IIIa inhibitors at initial PCI
Lasso di tempo: directly post PCI
|
Percentage of patients receiving thrombotic bail-out with GPIIb/IIIa inhibitors at initial PCI
|
directly post PCI
|
Complete (≥ 70%) ST-segment elevation resolution pre-PCI and 60 min post-PCI
Lasso di tempo: pre-PCI and 60 min post-PCI
|
Complete (≥ 70%) ST-segment elevation resolution pre-PCI and 60 min post-PCI
|
pre-PCI and 60 min post-PCI
|
Corrected TIMI frame count (cTFC) at angiography, pre and post PCI.
Lasso di tempo: pre PCI, directly post PCI
|
Corrected TIMI frame count (cTFC) at angiography, pre and post PCI
|
pre PCI, directly post PCI
|
TIMI myocardial perfusion grade (TMPG) at angiography, pre and post PCI.
Lasso di tempo: pre PCI, directly post PCI
|
TIMI myocardial perfusion grade (TMPG) at angiography, pre and post PCI.
|
pre PCI, directly post PCI
|
Time-relationship (from symptom onset to 1st dose intake) on each co-primary
Lasso di tempo: directly post-PCI
|
Time from symptom onset to 1st dose intake correlated to TIMI flow grade 3 of MI culprit vessel at initial angiography and on ≥70% ST-segment elevation resolution directly post-PCI
|
directly post-PCI
|
Time-relationship (from 1st dose intake to ECG/ angiography) on each co-primary
Lasso di tempo: directly post-PCI
|
Time from first dose intake to ECG correlated to ≥70% ST-segment elevation resolution directly post-PCI and time from randomization to initial angiography correlated to TIMI flow grade 3 of MI culprit vessel
|
directly post-PCI
|
TIMI flow grade 3 at end of procedure.
Lasso di tempo: directly post PCI
|
TIMI flow grade 3 at end of procedure.
|
directly post PCI
|
Myocardial Blush at the start and end of the procedure
Lasso di tempo: pre PCI, directly post PCI
|
Myocardial Blush at the start and end of the procedure
|
pre PCI, directly post PCI
|
Maximum CK, and CK-MB levels
Lasso di tempo: upto 72 hours after randomisation
|
Maximum CK, and CK-MB levels
|
upto 72 hours after randomisation
|
Level of platelet inhibition at first medical contact, beginning and end of PCI procedure, as well as at 4 hours after prasugrel administration
Lasso di tempo: at time of prasugrel administration, pre PCI, directly post PCI, 4 hours after prasugrel administration
|
Level of platelet inhibition at first medical contact, beginning and end of PCI procedure, as well as at 4 hours after prasugrel administration
|
at time of prasugrel administration, pre PCI, directly post PCI, 4 hours after prasugrel administration
|
Platelet reactivity, at each time point as well as over time
Lasso di tempo: at time of prasugrel administration, pre PCI, directly post PCI, 4 hours after prasugrel administration
|
PRU measurements at first medical contact, beginning and end of PCI, as well as 4hours after drug administration
|
at time of prasugrel administration, pre PCI, directly post PCI, 4 hours after prasugrel administration
|
Rates of HPR
Lasso di tempo: upto 72 hours after randomisation
|
Percentage of patients with PRU values over HPR threshold
|
upto 72 hours after randomisation
|
Exploratory analyses within each group to evaluate any differences in PD among patients receiving morphine
Lasso di tempo: upto 72 hours after randomisation
|
PD of each group among patients stratified for morphine treatment
|
upto 72 hours after randomisation
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: George Vlachojannis, MD, PhD, Maasstadziekenhuis
- Direttore dello studio: Pieter C Smits, MD, PhD, Maasstadziekenhuis
- Cattedra di studio: Nicolas van Mieghem, MD, PhD, Erasmus Medical Center
Pubblicazioni e link utili
Pubblicazioni generali
- Vlachojannis GJ, Wilschut JM, Vogel RF, Lemmert ME, Delewi R, Diletti R, van der Waarden NWPL, Nuis RJ, Paradies V, Alexopoulos D, Zijlstra F, Montalescot G, Angiolillo DJ, Krucoff MW, Van Mieghem NM, Smits PC. Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial. Circulation. 2020 Dec 15;142(24):2316-2328. doi: 10.1161/CIRCULATIONAHA.120.051532. Epub 2020 Oct 14.
- Vlachojannis GJ, Vogel RF, Wilschut JM, Lemmert ME, Delewi R, Diletti R, van Vliet R, van der Waarden N, Nuis RJ, Paradies V, Alexopoulos D, Zijlstra F, Montalescot G, Angiolillo DJ, Krucoff MW, Van Mieghem NM, Smits PC. COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial. Am Heart J. 2020 Jun;224:10-16. doi: 10.1016/j.ahj.2020.03.005. Epub 2020 Mar 11.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2017-40
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Prasugrel (Integral tablets)
-
The Queen Elizabeth HospitalCompletato
-
Eli Lilly and CompanyDaiichi Sankyo, Inc.Completato
-
Gyeongsang National University HospitalCompletatoSanguinamento | Sindrome coronarica acuta | Trombo piastrinicoCorea, Repubblica di
-
University of FloridaCompletato
-
University of MilanCompletato
-
University of FloridaCompletatoDisfunsione dell'arteria coronariaStati Uniti
-
University of PatrasCompletato
-
Medstar Health Research InstituteCompletatoSindrome coronarica acutaStati Uniti
-
VA Office of Research and DevelopmentCompletatoBypass coronaricoStati Uniti
-
Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo CompanyCompletatoSindrome coronarica acuta (ACS)Taiwan